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Abstract
Background: Cryptococcal meningitis (CM) is a major cause of mortality in HIV programmes in Africa despite
increasing access to antiretroviral therapy (ART). Mortality is driven in part by limited availability of amphotericin-based
treatment, drug-induced toxicities of amphotericin B deoxycholate and prolonged hospital admissions. A single, high-
dose of liposomal amphotericin (L-AmB, Ambisome) on a fluconazole backbone has been reported as non-inferior to
14 days of standard dose L-AmB in reducing fungal burden. This trial examines whether single, high-dose L-AmB given
with high-dose fluconazole and flucytosine is non-inferior to a seven-day course of amphotericin B deoxycholate plus
flucytosine (the current World Health Organization [WHO] recommended treatment regimen).
(Continued on next page)
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Methods: An open-label phase III randomised controlled non-inferiority trial conducted in five countries in sub-Saharan
Africa: Botswana, Malawi, South Africa, Uganda and Zimbabwe. The trial will compare CM induction therapy with (1) a
single dose (10 mg/kg) of L-AmB given with 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/day) to
(2) seven days amphotericin B deoxycholate (1 mg/kg/day) given alongside seven days of flucytosine (100 mg/kg/day)
followed by seven days of fluconazole (1200 mg/day). The primary endpoint is all-cause mortality at ten weeks with a
non-inferiority margin of 10% and 90% power. Secondary endpoints are early fungicidal activity, proportion of grade III/IV
adverse events, pharmacokinetic parameters and pharmacokinetic/pharmacodynamic associations, health service costs,
all-cause mortality within the first two and four weeks, all-cause mortality within the first ten weeks (superiority analysis)
and rates of CM relapse, immune reconstitution inflammatory syndrome and disability at ten weeks. A total of 850
patients aged ≥ 18 years with a first episode of HIV-associated CM will be enrolled (425 randomised to each arm). All
patients will be followed for 16 weeks. All patients will receive consolidation therapy with fluconazole 800 mg/day to
complete ten weeks of treatment, followed by fluconazole maintenance and ART as per local guidance.
Discussion: A safe, sustainable and easy to administer regimen of L-AmB that is non-inferior to seven days of daily
amphotericin B deoxycholate therapy may reduce the number of adverse events seen in patients treated with
amphotericin B deoxycholate and shorten hospital admissions, providing a highly favourable and implementable
alternative to the current WHO recommended first-line treatment.
Trial registration: ISRCTN, ISRCTN72509687. Registered on 13 July 2017.
Keywords: Cryptococcal meningitis, HIV, AmBisome, Amphotericin B, Fluconazole, Flucytosine, Clinical trial
Background
Early mortality among people initiating HIV treatment in
Africa is considerably higher than in high-income
countries [1–4]. Despite antiretroviral therapy (ART)
roll-out, approximately half of HIV-infected individuals in
sub-Saharan Africa are not on ART and about one-third
still present for care with very low CD4 counts. The inci-
dence of opportunistic co-infections such as CM in this
group is high [5] and CM remains the most common
cause of adult meningitis in much of Africa [6]. As a
result, cryptococcal meningitis (CM) is a major cause of
mortality in HIV-infected patients in Africa and is associ-
ated with 10–20% of all HIV-related deaths [7]. Further-
more, the number of CM cases remains high despite
increased ART access; they now include both ART-naïve
and ART-experienced patients, with half of patients diag-
nosed with CM having had prior exposure to ART but
with persisting low CD4 counts due to non-adherence
and/or ART failure [8–10]. The poor outcomes reported
using currently available antifungal therapy in African
centres are a critical driver of this high mortality. Mortal-
ity using amphotericin B deoxycholate-based therapy in
Africa, even in clinical trial settings, remains in the region
of 35–45% [10–13]. Amphotericin B deoxycholate therapy
requires hospitalisation for at least seven days and its tox-
icity profile requires costly laboratory monitoring. The
average hospitalisation cost for CM treated with ampho-
tericin B deoxycholate is USD 800–1000 in Zimbabwe
where the annual per capita gross domestic product is <
USD 1000. Many clinical centres in sub-Saharan Africa
lack access to reliable laboratory monitoring and have lim-
ited nursing capacity making safe administration of
conventional amphotericin B deoxycholate difficult or
impossible. Consequently, amphotericin B deoxycholate
therapy is often not available in Africa. Fluconazole, the
oral alternative widely used in Africa, is much less rapidly
fungicidal than amphotericin-B, even at a dosage of up to
1200 mg/day, and mortality at ten weeks is 50–60% [14,
15]. Given the HIV prevalence and incidence in Southern
and East Africa, inadequate ART coverage, suboptimal
monitoring of individuals on ART leading to treatment
failure and limited access to screening and pre-emptive
treatment for CM, CM will remain a major cause of
morbidity and mortality in the region for the foreseeable
future. New treatment strategies are urgently needed.
Until recently, World Health Organization (WHO)
treatment guidelines recommended a 14-day course of
amphotericin B deoxycholate-based treatment for CM
induction therapy. The recently completed phase III
ACTA trial showed that patients receiving a short,
seven-day course of amphotericin B deoxycholate plus
flucytosine had lower mortality at ten weeks (24%, 95%
confidence interval [CI]: 16–32) compared to patients
receiving 14-day course of amphotericin B plus flucyto-
sine (38%, 95% CI: 29–47, unadjusted hazard ratio [HR]
0.56, 95% CI: 0.35–0.91) [10]. The trial also confirmed
that flucytosine (5FC) is a significantly superior partner
drug for amphotericin B-based treatments compared
with fluconazole, leading to a substantial mortality
reduction of 38% (95% CI: 16–55, p = 0.002). As a
consequence, the WHO guidelines were revised and
now recommend first-line treatment with seven days of
amphotericin B deoxycholate and flucytosine 100 mg/
kg/day followed by seven days of fluconazole 1200 mg/
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day. In settings where flucytosine is unavailable, which
reflects most settings in Africa, the guidelines continue
to recommend 14 days of amphotericin B deoxycholate
with fluconazole [16].
A newer lipid-based formulation of amphotericin B
deoxycholate (L-AmB or AmBisome©) is particularly
suited for use in short-course yet highly effective induction
treatment for HIV-associated CM, due to: (1) the potential
for high dosing made possible by the lower rates of
drug-induced toxicity; and (2) the long tissue half-life. In
the context of HIV-associated CM, 14-day courses of con-
ventional amphotericin B deoxycholate are associated with
an average drop in haemoglobin of 2.3 g/dL and a mean
increase in creatinine of 73% [17]. Even at high doses,
L-AmB is associated with significantly less nephrotoxicity
and anaemia as well as lower rates of infusion reactions
than conventional amphotericin B deoxycholate [18]. The
long tissue half-life of L-AmB following high-dose adminis-
tration in patients is well-established [19–22], as is its
effective penetration into brain tissue [23]. The concept of
single or intermittent dosing with very high doses is also
established in both prophylaxis in haematology patients
and treatment of visceral leishmaniasis in lower- and
middle-income countries [24]. Single doses of up to
15 mg/kg have been safely given; doses of 10 mg/kg are
routinely given with demonstration of efficacy for treat-
ment of visceral leishmaniasis and invasive fungal infec-
tions [24, 25]. Pharmacokinetic data from animal models
[20] and humans [19] suggest that increasing L-AmB dos-
ing from the currently recommended 3–4 mg/kg may lead
to improved outcomes and, as with standard amphotericin
B, that intermittent dosing regimens may be as effective as
daily therapy [20]. Although L-AmB is recommended as
treatment for HIV-associated CM in several national
guidelines, optimal dosing is unknown and the strategy of
short-course high dosing of L-AmB has not yet been tested
in a phase III clinical trial [18].
A randomised controlled trial comparing L-AmB
3 mg/kg/day, L-AmB 6 mg/kg/day and amphotericin B
deoxycholate 0.7 mg/kg/day, all given for 14 days,
showed no difference in mortality outcome between
any of these regimens [18]; 3 mg/kg/day is widely used
as the standard dose. However, murine models suggest
dosing of 3 mg/kg/day may be sub-optimal [20]. Fur-
ther evidence to support this comes from the recently
completed phase II AMBITION trial which was per-
formed with the primary objective of determining the
rate of cryptococcal clearance from cerebrospinal fluid
(CSF), presented as Early Fungicidal Activity (EFA), of
three alternative schedules of intermittent high-dose
L-AmB in comparison with 14 days of standard daily
L-AmB for induction therapy for HIV-associated CM
[26]. Eighty participants were recruited at sites in
Botswana and Tanzania and randomised to one of four
treatment arms: (1) L-AmB 10 mg/kg day 1 (single
dose); (2) L-AmB 10 mg/kg day 1, L-AmB 5 mg/kg day
3 (two doses); (3) L-AmB 10 mg/kg day 1, L-AmB
5 mg/kg days 3 and 7 (three doses); or (4) the control
arm, being standard 14-day L-AmB (3 mg/kg/day). All
treatment arms received high-dose fluconazole
(1200 mg/day) for 14 days. This phase II trial was
stopped by the Data Monitoring Committee (DMC) at
the pre-planned interim analysis stage of 80 patients as
the primary endpoint had been reached with the rec-
ommendation that the trial proceed onto the current
clinical endpoint phase III trial using single dose
L-AmB. The primary analysis showed that the EFA in
all three short-course high-dose arms was comparable
to, or greater than, the control arm, with statistical
non-inferiority between all short-course arms and con-
trol at the pre-defined non-inferiority (NI) of 0.2 log10
colony forming units (CFU)/mL/day difference (Fig. 1).
There was no evidence for any dose response effect
with additional L-AmB doses, suggesting maximal fun-
gicidal activity was achieved with a single 10 mg/kg
dose. All three high-dose short-course L-AmB regimens
were well tolerated, with only one Division of AIDS
(DAIDS) grade IV laboratory toxicity event occurring
during induction therapy, and a total of seven grade III
and no grade IV clinical adverse events (AEs) associated
with high-dose L-AmB. This toxicity profile compared
to 33% of patients reporting grade III or IV anaemia in
a combined cohort of 368 patients treated in Africa
with conventional amphotericin B for 14 days [27].
There were no safety concerns with short-course treat-
ment and no patients receiving short-course L-AmB re-
quired additional ‘rescue’ L-AmB therapy. Overall
mortality in the trial was 29% at ten weeks, comparing
very favourably with recent trials of amphotericin B
deoxycholate-based treatments, with no significant dif-
ference between arms [17].
However, although EFA is an extremely valuable
tool to rapidly screen novel antifungal treatment regi-
mens and is associated with mortality [28], it has not
been validated as a true ‘surrogate’ marker of out-
come. Large phase III trials with a mortality endpoint
are critical to define the optimal treatment regimens
for HIV-associated CM and are essential to influence
policy.
Method/design
Study design
The AMBITION trial is an open label, phase III, rando-
mised controlled non-inferiority, multi-centre trial to
compare single, high-dose L-AmB treatment to
seven-day amphotericin B deoxycholate-based treatment
for HIV-associated CM (Additional files 1 and 2).
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Hypothesis
Short-course, high-dose L-AmB given with 14 days of
high-dose fluconazole and flucytosine will be non-inferior
to seven days of daily-dosed amphotericin B deoxycholate
given with seven days of flucytosine, followed by seven
days of high-dose fluconazole, for the treatment of
HIV-associated CM with all-cause mortality as the
primary efficacy endpoint.
Objectives
The primary objective is to determine whether single,
high-dose L-AmB given with 14 days of high-dose
fluconazole and flucytosine is non-inferior to seven days
of daily-dosed amphotericin B deoxycholate given with
seven days of flucytosine, followed by seven days of
high-dose fluconazole in terms of all-cause mortality in
HIV-associated CM patients.
Setting
The trial will be conducted in six large referral hospitals
across five countries in sub-Saharan Africa. The sites
include: Princess Marina Hospital, Gaborone, Botswana;
Mitchells Plain District Hospital, Cape Town, South Africa;
Parirenyatwa Central Hospital, Harare, Zimbabwe; Queen
Elizabeth Central Hospital, Blantyre, Malawi; Kamuzu
Central Hospital, Lilongwe, Malawi; and the Infectious
Diseases Institute, Kampala and Mbarara, Uganda.
Outcome measures
The primary outcome measure is all-cause mortality
within the first ten weeks after randomisation (non-inferi-
ority). Secondary outcome measures include: EFA derived
from serial lumbar punctures (LPs) on days 1, 7 and 14;
proportions of patients in each arm developing clinical
and DAIDS laboratory-defined grade III/IV AEs; median
% change from baseline in laboratory defined parameters;
PK parameters and PK/PD associations of single high-
dose L-AmB; health service costs; all-cause mortality
within the first two and four weeks; all-cause mortality
within the first ten weeks (superiority analysis); rates of
cryptococcal relapse / IRIS within the first ten weeks; and
disability at ten weeks.
Sample size
The WHO now recommends seven days amphotericin B
deoxycholate-based regimens for the treatment of CM if
flucytosine is available as an adjunctive antifungal. A
non-inferiority design has been chosen as the primary aim
of this trial is to identify an alternative safe and easy to
administer short-course L-AmB treatment regimen that
can be implemented in settings where giving amphotericin
B deoxycholate-based treatment is difficult or impossible.
An efficacious single dose L-AmB treatment would also
markedly facilitate CM therapy in settings currently using
amphotericin B deoxycholate-based treatment, reducing
the duration of hospitalisation and the associated risks (e.g.
nosocomial sepsis) and costs. Ten-week mortality in our
previous trials using amphotericin B deoxycholate-based
regimens at the study sites has been in the range of 28–
41% [13, 29]; it was 30% with short-course high-dose
L-AmB treatments in the recent phase II study. Assuming
35% ten-week mortality in both the control and test groups
and using a 10% non-inferiority margin (i.e. the upper mar-
gin of the one-sided 95% CI of the difference in ten-week
Fig. 1 Primary and key secondary outcomes of the AMBITION Step I phase-II randomised controlled trial. The figure shows: (a) all three short-
course treatment arms were non-inferior to control; (b) EFA and the individual patient slopes over the initial 14 days of treatment; and (c) all
three short-course treatment arms remained non-inferior to control when controlling for baseline fungal burden (QCC), baseline CD4 count,
baseline mental status, QCC and CD4 count, QCC count, CD4 count, mental status and QCC, CD4 count, mental status, sex, age and ART
status [26]
Lawrence et al. Trials          (2018) 19:649 Page 4 of 13
mortality between the two arms does not exceed 10%) and
one-sided 5% type one error, 390 participants would be
required per arm to achieve 90% power. This sample size
will also have 83.25% power at a one-sided α = 0.025 or
two-sided α = 0.05. The 10% non-inferiority margin has
been chosen to ensure that only clinically unimportant
differences are deemed non-inferior and is in keeping with
conventional practice. If the ten-week mortality is
increased to 40% the equivalent sample size is 412 per arm.
Making a conservative allowance for withdrawals and
losses to follow-up of up to 8% (losses are in the range of
2–4% in similar trials [10]), or a higher than anticipated
mortality rate, we plan to enrol 425 participants per arm.
Thus, we will randomise a total of 850 participants. This
will be the largest CM treatment trial conducted in Africa.
Inclusion and exclusion criteria
Consecutive patients aged ≥ 18 years with a first episode of
CM (confirmed by either India ink or cryptococcal antigen
[CrAg] test in the CSF) will be enrolled. Participants must
be HIV-infected or willing to undertake an HIV test if their
status is unknown. Participants must provide written
informed consent or, if unable to consent, have a next of
kin who agrees to the patient participating in the study,
providing written consent. Pregnant (confirmed by urinary
or serum pregnancy test) or lactating women, patients with
a previous serious reaction to study drugs, or patients on
antifungal treatment at CM treatment doses (amphotericin
B deoxycholate ≥ 0.7 mg/kg or fluconazole ≥ 800 mg/day)
for > 48 h or concomitant medication that is contraindi-
cated with the study drugs at the time of assessment will
be excluded.
Consent
Written informed consent to enter the trial and be rando-
mised will be obtained from participants or, in the case of
those lacking capacity to consent, from next of kin with
legal responsibility (if appropriate and in keeping with na-
tional guidance and regulations). Consent will be obtained
after explanation of the aims, methods, benefits and poten-
tial hazards of the trial, and before any trial-specific proce-
dures are performed or any blood is taken for the trial.
Once the patient’s mental status improves and they regain
the capacity to consent, persons enrolled via surrogate
consent will be re-consented, with care taken to ensure
they understand that they are: (1) free to withdraw from
the research study; and (2) if they do withdraw, this will
not jeopardise their future care. Patients who withdraw will
revert to the standard of care at the treatment site (usually
amphotericin B deoxycholate and fluconazole daily for two
weeks or fluconazole monotherapy for two weeks). It will
be made unambiguously clear that the participant (or
guardian) is free to refuse to participate in all or any aspect
of the research trial, at any time and for any reason,
without incurring any penalty or affecting their access to
the standard treatment available at the recruiting site (or
that of their relative). Separate consent forms will be com-
pleted for the storage and/or genetic analysis of samples as
determined by local guidelines. Original signed consent
forms will be kept by the investigator and documented in
the electronic case report form (eCRF), a copy given to the
participant or family and a copy placed in the participant’s
medical notes.
Allocation
Patients will be randomised individually using a
computer-generated programme. Randomisation codes will
be generated via a permuted-block randomisation method
and stratified by site. Block sizes will vary at four and six.
Randomisation lists will be created for each site by an inde-
pendent statistician and each list will be housed on the
electronic data capture system (EDC) for that particular
site. The full lists will be inaccessible to trial staff. Rando-
mised allocation for each trial participant will be provided
to trial staff from the randomisation list for that site. In-
ternally, the EDC selects against the electronic randomisa-
tion and guarantees to make the selection in the natural
order of the list. Once a selection is made, the randomisa-
tion record is tagged with the participant study allocated
identifier, date and time of randomisation, and other EDC
system audit values (username, machine name, etc).
Interventions
Participants will be randomised to receive either intraven-
ous L-AmB 10 mg/kg on day 1 given with 14 days of oral
fluconazole 1200 mg/day and oral flucytosine 100 mg/kg/
day (intervention) or intravenous amphotericin B deoxy-
cholate 1 mg/kg/d for seven days given with seven days of
oral flucytosine 100 mg/kg/day followed by seven days of
oral fluconazole 1200 mg/day (control) (Fig. 2). After the
two-week induction phase, all participants will then
receive oral fluconazole 800 mg/day to complete ten
weeks therapy and 200 mg/day thereafter. ART will be
commenced four to six weeks after initiation of antifungal
therapy, in line with national guidelines. Given the com-
bination of oral and intravenous therapies, the differing
duration in days of intravenous therapy and the known
drug-induced toxicities that require monitoring and man-
aging, blinding of treatment allocation was deemed to be
impractical. To counter this, an objective endpoint of
all-cause mortality has been chosen. In addition, all staff
performing quantitative cell cultures are blind to treat-
ment, as are coordinating investigators, including the Trial
Management Group (TMG) members.
Rescue medication
Although the results from our phase II trial demonstrate
that it is unlikely that CSF fungal burden will increase
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after initiation of treatment, if the day 7 LP identifies an
increase in CFU from baseline this will be reported as a
serious adverse event (SAE) and experienced, senior cli-
nicians at the coordinating centre will be responsible for
managing this situation on a case-by-case basis to ensure
all participants receive effective induction therapy.
Schedule
All participants will be admitted to hospital for a minimum
of one week. As the induction phase occurs over two
weeks if participants are well enough to be discharged after
day 7 and before day 14, treatment will be given under
close outpatient supervision during the second week, en-
suring compliance to the trial intervention and facilitating
close clinical and laboratory monitoring. After the intensive
phase, participants will be seen in clinic at four, six, eight
and ten weeks and a single telephone follow-up to ascer-
tain vital status and level of disability will be made at week
16. Every effort will be made (e.g. with mobile telephone
calls, home visits and financial help with travelling ex-
penses) to obtain accurate and complete follow-up data for
ten weeks after the start of treatment. Particular attention
will be paid to the possibility, in ART-naïve participants, of
developing IRIS after starting ART [30].
Participants will have a full history and examination at
baseline (Table 1). Blood will be drawn for full blood
count (FBC), urea, creatinine, electrolytes and alanine
transaminase (ALT). If unknown, HIV serology will be
Fig. 2 Trial schema. Trial entry, randomisation and treatment. ART antiretroviral therapy, EFA early fungicidal activity, PD pharmacodynamics, PK
pharmacokinetics, SAE serious adverse event
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performed in addition to CD4 and viral load samples, as
clinically indicated. Women of reproductive age will
have a pregnancy test (urine or serum). All participants
will have an LP for opening pressure, total and differen-
tial white cell count, protein, glucose, India ink, CrAg,
routine culture, quantitative fungal culture and immune
parameters. Further blood samples will be collected on
days 3, 5, 7, 10, 12, 14 and 28 for urea and creatinine.
FBC and ALT will be repeated on days 7, 14 and 28.
Additional samples will be taken alongside monitoring
blood tests for sub-studies, including PK/PD studies. LPs
will be repeated on days 7 and 14 for opening pressure,
quantitative fungal culture, CSF drug levels and immune
parameters. Raised intracranial pressure will be managed
with LPs as per a standard operating procedure. Crypto-
coccal clearance rates will be calculated using summary
statistics for each patient: the rate of decrease in log10
CFU per mL CSF per day derived from the slope of the
linear regression of log10 CFU against time for each pa-
tient. A linear regression model will be used to compare
mean rates of decline EFA for each arm, giving summary
differences with 95% CI and significance levels [31, 32].
We will adjust analyses for potential confounding fac-
tors, including baseline fungal burden. Disability at ten
weeks will be assessed using two simple questions and a
modified Rankin scale.
Statistical methods
The primary endpoint (all-cause mortality at ten weeks)
will be analysed using a generalised linear model (GLM).
The model will have treatment group as the sole predictor,
a binomial distribution and an identity-link function, from
which the (unadjusted) risk difference between the treat-
ment groups and its one-sided 95% CI will be estimated. If
the upper limit of the one-sided 95% CI falls below the
non-inferiority margin of 10%, non-inferiority will be de-
clared. Sensitivity analyses of the primary endpoint mak-
ing different assumptions for the losses to follow-up will
be conducted. Covariate-adjusted analyses for the primary
endpoint will be conducted by adding pre-specified covar-
iates into the GLM model to derive the adjusted risk
difference and the upper limit of one-sided 95% CI. Im-
putation for baseline missing covariates will be made for
the covariate-adjusted analysis. Subgroup analysis of the
primary endpoint will also be performed on prespecified
covariates.
The analyses of the secondary endpoints will be based
on superiority test using a 5% two-sided significance
level. Analyses of survival data will be conducted using
unadjusted Cox regression analysis to calculate the HR
and 95% CI between the treatment groups. Kaplan–
Meier survival curves by treatment group will be calcu-
lated and displayed. A log-rank test will be conducted to
compare the survival curves between the treatment
groups. Analyses of binary secondary outcomes will be
performed in a similar way as the primary endpoint
analysis using GLMs with treatment group as the sole pre-
dictor. The point estimate of the treatment effect with
two-sided 95% CI will be derived. The safety analysis will
be descriptive and the frequency and proportions of par-
ticipants suffering clinical and laboratory-defined side ef-
fects will be generated by treatment arms. Other statistical
analyses may be performed if deemed necessary.
Data will be analysed using SAS 9.4 and Stata 13.
Findings will be reported according to the Consolidated
Standards of Reporting Trials (CONSORT) guidelines
for randomised controlled trials. Primary analyses will be
based on the intention-to-treat population and second-
ary analyses will be based on the per-protocol popula-
tion. All analyses will be described in detail in the
finalised and signed statistical analysis plan before data
are locked and unblinding occurs.
Dissemination of results
The results of the trial will be analysed, presented and
published as soon as possible. The TMG will form the
basis of the Writing Committee and will advise on the
nature of the publication. The names of all investigators
will be included in the authorship of any publication. An
authorship policy will be agreed by all investigators be-
fore the commencement of the trial. The independent
members of the Trial Steering Committee (TSC) and
DMC will be listed with their affiliations in the acknowl-
edgements or appendix sections of the main publication.
The funders will have no role in the decision to publish
or the content of the publication.
Ethical approval
The Research Ethics Committee of the London School of
Hygiene and Tropical Medicine have approved the protocol
v2.1 07.11.17 (ref. 14,355). Approval has also been granted
by the following: University of Botswana Office of Research
and Development (UBR/RES/IRB/BIO/042); Botswana
Ministry of Health and Wellness Health Research and
Development Division (HPDME:13/18/1); Princess Marina
Hospital Research and Ethics Committee (PMH 5/
79(407-1-2017); University of Cape Town Human Research
Ethics Committee (642/2017); Malawi National Health
Sciences Research Committee (1907); Mulago Hospital
Research and Ethics Committee (MHREC 1297); and the
Medical Research Council of Zimbabwe (MRCZ/A/2263).
Any amendments will be submitted and approved by each
ethics committee.
Timeline
In total, 850 participants will be recruited over a
three-year period with a planned trial completion date of
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31 December 2020. This is feasible based upon previous
experience and rates of CM at the hospital sites.
Ancillary studies
PK/PD
The PK/PD of L-AmB, fluconazole and flucytosine and
the impact of PK variability on outcome will be
described. Plasma samples will be collected at the end of
the L-AmB infusion and then at 2, 4, 8, 12 and 24 h in a
sub-study of participants at the Blantyre study site. A
portion (0.5 mL) of the CSF sample obtained for quanti-
tative counts will be reserved to measure fluconazole
and flucytosine concentrations and thereby estimate the
extent of penetration of these drugs into the CSF.
Amphotericin levels will not be measured in CSF since
they are known to be negligible. A PK-PD model will be
constructed to explore the persistence of amphotericin B
within the central nervous system and the resultant anti-
fungal effect. Amphotericin penetration into the CNS
will be estimated using compartmental modelling
techniques. Monte Carlo simulation will enable further
insights into the regimen(s) that may be associated with
maximal antifungal activity.
Economic analysis
An economic analysis will be conducted to provide evi-
dence for the cost-effectiveness of short-course L-AmB
treatment. The objective of the economic analysis is to es-
timate the cost consequences and the cost-effectiveness of
short-course L-AmB treatment compared to current care.
Both societal and healthcare perspectives are chosen and
health service patient costs including household costs,
treatment cost and hospitalisations in both arms will be
compared over the trial period in a probabilistic approach,
using Monte Carlo bootstrapping methods in STATA,
@Risk software and TreeAge. In the country-specific
cost-consequence analyses, the societal and health service
costs will be compared and used along with the trial-wide
primary endpoint data to perform cost-effectiveness mod-
elling using a decision-tree model for each country with
historical data as comparison.
Semi-quantitative CrAg testing and diagnostic quantitative
polymerase chain reaction (PCR)
A newly developed point of care, lateral flow, semi-quanti-
tative CrAg test is now available from Institut Pasteur and
Biosynex. We will use this semi-quantitative test in real
time to determine antigen titre at baseline, in blood and
CSF, and compare results to the currently established point
of care test. Secondary trial analyses will include the associ-
ation of baseline titre with outcome and exploration of the
possibility of a differential treatment response between
arms according to baseline titre. If such a differential re-
sponse was observed, this sub-study could provide the
rationale for and demonstrate the means for individualised
treatment, based on a rapid assessment of antigen load. A
novel diagnostic quantitative PCR (DNA and RNA) tool
will be also be used in each treatment arm and correlated
with quantitative culture counts. We aim to estimate the
fungal load and fungal viability in blood and CSF at base-
line using the PCR in addition to fungal load kinetics on
treatment. The objective will be to develop a practical
alternative to time-consuming quantitative cultures in
order to improve detection of fungaemia and measurement
of fungal burden and develop a novel biomarker for asses-
sing the best fungicidal treatments in this and subsequent
research studies.
Quality control and assurance
Trial oversight will be provided by the TMG, TSC and
Independent DMC. The study sponsor is the London
School of Hygiene and Tropical Medicine. The sites will
be monitored at regular intervals with visits by the trial
manager/monitor in order to monitor the conduct of
the trial and ensure that the principles of International
Conference of Harmonisation (ICH) Good Clinical Prac-
tice (GCP) are being adhered to. Sites will be visited by
an internal monitor for initiation visits before starting
recruitment, after the first 10–15 participants, at 40%
and 70% of recruitment targets and at trial closure, with
additional visits made if required. Visits will ensure that
all training has been completed, that drug supply and
equipment are in place and that all staff are up to date
on the protocol and procedures. A monitor from the
Sponsor will visit at least three of the six sites. Central
monitoring will be performed in addition to the on-site
monitoring procedures. Bimonthly reports on the pro-
gress of the trial as well as the frequency of DAIDS
laboratory-defined grade III/IV AEs/SAEs/suspected un-
expected serious adverse events (SUSARs) will be com-
piled by the trial manager/statistician and reviewed by
the Sponsor. All Grade IV AEs, all SAEs and all SUSARs
will be reported to the TMG within 24 h [27].
Data collection and data management
eCRF data collected and validated using the EDC will be
stored in an electronic database that is protected using a
scheme of authentication and encryption. Paper docu-
ments, such as clinical notes and administrative documen-
tation, will be kept in a secure location and held for at
least five years after the end of the trial. During this period,
all data should be accessible to the competent or equiva-
lent authorities, the sponsor and other relevant parties
with suitable notice. Security of electronic records and
data is a significant concern. All components of the
distributed data systems will use authentication and
encryption to render subject identity and personal health
information unusable, unreadable or indecipherable to
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unauthorised individuals. Full drive encryption will be im-
plemented at the hardware layer of all devices storing pro-
tected health information. A three-factor scheme will be
used to authenticate users through the hardware layer to
the application layer where personal health information is
available. The applications will have user profiles to con-
trol access to certain data and reports. The application and
database layers will use a combination of hashing and en-
cryption for sensitive and personal data. Mobile devices
and the staff operating them will not be equipped with the
encryption keys to decrypt selected sensitive data fields.
Confidentiality
We will follow the principles of the UK Data Protection
Act (DPA) regardless of the countries where the trial is
being conducted. Consent forms will be stored under
the supervision of each local primary investigator (PI) in
a secured office and accessible to trial staff only. Partici-
pants’ personal details are stored in an encrypted, separ-
ate server to the main database and participants are
identified by their study number throughout the trial.
Termination of the study
The trial will be considered closed when the last patient
has completed ten weeks of active follow-up in the
study, the 16-week telephonic follow-up call, and all
follow-up and laboratory reports, including repeat
plasma HIV viral load testing in ART failure cases, have
been received. Early termination could occur if the
DMC decides there is an unacceptable level of AEs in
either test arm or if the intervention arm is shown to be
inferior with stringent p value testing.
Indemnity
The sponsor of the trial is the London School of
Hygiene and Tropical Medicine and as such provides in-
demnity for the trial. All personnel involved in the trial
will be expected to be indemnified by their employing
authority. Local insurance will be taken out where local
regulations require this.
Discussion
The potential impact of a safe, sustainable regimen of
high-dose L-AmB with non-inferior efficacy when com-
pared to one week of daily-dosed amphotericin B deoxy-
cholate would be to reduce the number of AEs seen in
patients treated with amphotericin and shorten the
length of hospital admissions. It is hoped that our eco-
nomic analysis will demonstrate the cost-effectiveness of
this intervention across all our sites in southern Africa
and provide a highly favourable alternative to the
current WHO-recommended first-line treatment.
Trial status
The study is jointly funded through the European and De-
veloping Countries Clinical Trials Partnership (EDCTP),
Swedish International Development Cooperation Agency
(SIDA) and Wellcome Trust / Medical Research Council
(UK) / UKAID Joint Global Health Trials. Recruitment
commenced in Botswana in January 2018 and in South
Africa in July 2018; recruitment will commence at the
other sites pending the requisite ethical and regulatory
approvals.
Additional files
Additional file 1: AMBITION Study Protocol v2.1 date: 7th November
2017. (PDF 1954 kb)
Additional file 2: AMBITION Study SPIRIT Checklist. (DOC 121 kb)
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